AACR 2019 Gilteritinib improved survival for patients with acute myeloid leukaemia

AACR 2019: Gilteritinib improved survival for patients with acute myeloid leukaemia

07:28 EDT 2 Apr 2019 | ecancermedicalscience

Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukaemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from...

More From BioPortfolio on "AACR 2019: Gilteritinib improved survival for patients with acute myeloid leukaemia"